Title:
ANTITUMOR AGENT
Document Type and Number:
WIPO Patent Application WO/2019/107386
Kind Code:
A1
Abstract:
The present invention provides a method for enhancing an antitumor effect by a compound that strongly inhibits ribonucleotide reductase (RNR) or a salt of said compound. A combination formulation in which a sulfonamide compound that has RNR inhibitory activity and is represented by formula (I) (in the formula, X1 represents an oxygen atom, etc.; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom, etc.; R1 represents -C(R11)(R12)-, etc.; R11 and R12 are the same or different and represent a hydrogen atom, etc.; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group, etc.; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group, etc.; and R4 represents a hydrogen atom, etc.), or a salt thereof, is administered in combination with another antitumor agent.
Inventors:
UENO HIROYUKI (JP)
HOSHINO TAKUYA (JP)
HOSHINO TAKUYA (JP)
Application Number:
PCT/JP2018/043697
Publication Date:
June 06, 2019
Filing Date:
November 28, 2018
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/4245; A61K45/00; A61P35/00; A61P43/00; C07D249/04
Domestic Patent References:
| WO2017209155A1 | 2017-12-07 | |||
| WO2017150725A1 | 2017-09-08 | |||
| WO2017111074A1 | 2017-06-29 | |||
| WO2011071565A1 | 2011-06-16 |
Foreign References:
| JP2017229681A | 2017-11-29 |
Other References:
ANNU. REV. BIOCHEM., vol. 67, 1998, pages 71 - 98
J. BIOL. CHEM., vol. 245, 1970, pages 5228 - 5233
NAT. COMMUN., vol. 5, 2014, pages 3128
CLIN. SCI., vol. 124, 2013, pages 567 - 578
EXPERT. OPIN. THER. TARGETS, vol. 17, 2013, pages 1423 - 1437
BIOCHEM. PHARMACOL., vol. 59, 2000, pages 983 - 991
BIOCHEM. PHARMACOL., vol. 78, 2009, pages 1178 - 11 85
CANCER RES., vol. 54, 1994, pages 3686 - 3691
PHARMACOL. REV., vol. 57, 2005, pages 547 - 583
FUTURE ONCOL., vol. 8, 2012, pages 145 - 150
BIOCHEM. PHARMACOL., vol. 73, 2007, pages 1548 - 1557
TETRAHEDORON LETT., vol. 51, 2010, pages 418 - 421
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceuticals", pages: 163 - 198
"GenBank", Database accession no. NM-001034
CANCER RESEARCH, vol. 64, 2004, pages 1 - 6
TRENDS PHARMACOL. SCI., vol. 4, 1983, pages 450 - 454
PHARMACOL. REV., vol. 58, no. 3, 2006, pages 621 - 681
SYNERGY, vol. 1, 2014, pages 3 - 21
See also references of EP 3718545A4
J. BIOL. CHEM., vol. 245, 1970, pages 5228 - 5233
NAT. COMMUN., vol. 5, 2014, pages 3128
CLIN. SCI., vol. 124, 2013, pages 567 - 578
EXPERT. OPIN. THER. TARGETS, vol. 17, 2013, pages 1423 - 1437
BIOCHEM. PHARMACOL., vol. 59, 2000, pages 983 - 991
BIOCHEM. PHARMACOL., vol. 78, 2009, pages 1178 - 11 85
CANCER RES., vol. 54, 1994, pages 3686 - 3691
PHARMACOL. REV., vol. 57, 2005, pages 547 - 583
FUTURE ONCOL., vol. 8, 2012, pages 145 - 150
BIOCHEM. PHARMACOL., vol. 73, 2007, pages 1548 - 1557
TETRAHEDORON LETT., vol. 51, 2010, pages 418 - 421
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceuticals", pages: 163 - 198
"GenBank", Database accession no. NM-001034
CANCER RESEARCH, vol. 64, 2004, pages 1 - 6
TRENDS PHARMACOL. SCI., vol. 4, 1983, pages 450 - 454
PHARMACOL. REV., vol. 58, no. 3, 2006, pages 621 - 681
SYNERGY, vol. 1, 2014, pages 3 - 21
See also references of EP 3718545A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: